The new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly
|
|
- Geoffrey Dennis
- 2 years ago
- Views:
Transcription
1 The new oral anticoagulants & the future of haemostasis laboratory testing Emmanuel J Favaloro Diagnostic Haemostasis Laboratory, Institute of Clinical Pathology & Medical Research, ICPMR, Pathology West, NSW 2145 Australia Alcohol: the good, the bad and the ugly
2 3 Anticoagulants / antithrombotics Many clinical indications Main existing agents: Vitamin K antagonists (VKAs) such as warfarin (very common): Prophylaxis, treatment of pulmonary embolism (PE), venous thrombosis and its extension, thromboembolic complications assoc with atrial fibrillation (AF); coronary occlusion adjunctive treatment. Unfractionated heparin (common / less common): Prophylaxis and treatment of thromboembolic disorders, e.g. thrombophlebitis, PE and occlusive vascular disease. Also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. Low molecular weight heparin (common): Prevention of venous thromboembolism (surgical, acutely unwell bedridden medical patients), extracorporeal thrombosis during haemodialysis. Treatment of established deep vein thrombosis (DVT); unstable angina, non-q-wave MI (with aspirin); acute ST-segment elevation MI (STEMI) (+ thrombolytic) Garcia DA, et al. Chest 2012;141(Suppl 2):e24S e43s Favaloro et al. Pathology 2011; 43: Current routine tests and current anticoagulant monitoring Prothrombin time / International Normalised Ratio (PT / INR). Vitamin K antagonists (VKAs) such as warfarin (very common) Therapeutic range (INR): Heart valves ; other indications Activated Partial Thromboplastin Time (APTT). Unfractionated heparin (uncommon) Therapeutic range: s (~ x baseline or 0.3 to 0.7 U/mL heparin by anti-xa assay). Thrombin Time (TT). Unfractionated heparin (uncommon) No therapeutic range: TT is prolonged by unfractionated heparin. Anti-Xa assay. Unfractionated heparin and/or low molecular weight heparin (uncommon) Therapeutic ranges: 0.3 to 0.7 U/mL (unfractionated heparin) to U/mL (low molecular weight heparin). Favaloro & Adcock. Semin Thromb Hemost 2008;34: Cuker. Semin Thromb Hemost 2012;38: Favaloro et al. Pathology 2011; 43:
3 PT, APTT & TT: INR & VKAs: Anticoagulant control points NB: INR = (PT/MNPT) ISI 5 Favaloro et al. Pathology 2011; 43: Favaloro et al. Pathology 2011; 43:
4 Heparin - anticoagulant control points: New oral anticoagulants / antithrombotics Many coming Main agents & current indications (Australia): Dabigatran (etexilate; Pradaxa; Boehringer Ingelheim Pty Ltd): Direct thrombin inhibitor: Venous thromboembolic event (VTE) prevention in adults after major lower limb orthopaedic surgery (elective total hip, knee replacement); stroke, systemic embolism prevention in nonvalvular AF with greater than or equal to 1 additional stroke risk factor. Rivaroxaban (Xarelto; Bayer Ltd): Direct Factor Xa inhibitor: VTE prevention in adults after major orthopaedic surgery of lower limbs (elective total hip, knee replacement); prevention of stroke, systemic embolism in nonvalvular AF + at least 1 additional stroke risk factor; treatment of DVT, prevention of recurrent DVT, PE. Apixaban (Eliquis; Bristol-Myers Squibb Pharmaceuticals): Direct Factor Xa inhibitor: Venous thromboembolic event prevention in adults following elective total hip, total knee replacement surgery. 7 Favaloro et al. Pathology 2011; 43: Favaloro et al. Pathology 2011; 43: MIMS 4
5 New oral anticoagulants / antithrombotics New oral anticoagulants & anticoagulant control points: 9 Garcia et al. Blood : Favaloro et al. Pathology 2011; 43:
6 New oral anticoagulants vs heparin anticoagulant control points: Alcohol: Some positive effects for moderate intake Evidence for beneficial effects to coronary system Termed the French Paradox in 1992 (low incidence of cardiovascular disease in French people despite relatively high dietary intake of saturated fats). Most evidence relates to positive effects of red wine Some negative effects for excess intake Chronic heavy alcohol consumption and binge drinking associated with increased risk of cardiovascular effects Other adverse health outcomes (e.g. liver disease, mental disturbances, memory loss) Antisocial effects (increased aggression, violence, etc) 11 Favaloro et al. Pathology 2011; 43:
7 Alcohol: Alcohol:
8 New oral anticoagulants / antithrombotics Current routine tests and new anticoagulant drugs Have been developed without need for monitoring Clinical trials limited laboratory testing & defined patient populations (many conditions excluded) Marketing strategy - no monitoring required Post release - real world settings Many adverse events & some deaths no monitoring required / limited laboratory testing - how to assess? Plethora of subsequent publications regarding testing Why test? NOT drug monitoring (not like Warfarin) Patient presents with adverse events (i.e. thrombosis or haemorrhage) Patient known to be on anticoagulant: drug failure or patient compliance? Patient unknown to be on anticoagulant: unconscious trauma acute bleeding Either case: necessity of immediate reversal of anticoagulation? Patients requiring surgery (known / unknown to be on anticoagulant)? Patients with renal failure & known to be on anticoagulant? Patient types excluded in clinical trials & known to be on anticoagulant? Prothrombin time / International Normalised Ratio (PT / INR). INR not designed for use with the new oral anticoagulants PT variably prolonged by both Dabigatran and Rivaroxaban depending on reagent & drug level In general, PT more sensitive to Rivaroxaban than Dabigatran. Many PT reagents relatively insensitive to Dabigatran Activated Partial Thromboplastin Time (APTT). APTT variably prolonged by both Dabigatran and Rivaroxaban depending on reagent & drug level In general, APTT more sensitive to Dabigatran than Rivaroxaban. Many APTT reagents relatively insensitive to Rivaroxaban. Thrombin Time (TT). Standard TT over sensitive to Dabigatran but unresponsive to Rivaroxaban. Anti-Xa assay. Standard anti-xa assay over sensitive to Rivaroxaban but unresponsive to Dabigatran. No therapeutic range for these anticoagulants with any test or test reagent 15 Favaloro et al. Pathology 2011; 43: Favaloro et al. Clin Chem Lab Med 2011; 49(5): Harenberg J, et al. Semin Thromb Hemost 2012;38:16-22 Harenberg J, et al. Semin Thromb Hemost 2012;38: Favaloro et al. Pathology 2011; 43:
9 Current routine tests and new anticoagulant drugs - PT Current routine tests and new anticoagulant drugs - APTT 1. In general, PT more sensitive to Rivaroxaban than Dabigatran 2. Not all PT reagents sensitive to Rivaroxaban 3. No therapeutic range for these anticoagulants with any test or test reagent 1. In general, APTT more sensitive to Dabigatran than Rivaroxaban 2. Not all APTT reagents equally sensitive to Dabigatran 3. No therapeutic range for these anticoagulants with any test or test reagent 17 Harenberg J, et al. Semin Thromb Hemost 2012;38:16-22 Harenberg J, et al. Semin Thromb Hemost 2012;38: Harenberg J, et al. Semin Thromb Hemost 2012;38:16-22 Harenberg J, et al. Semin Thromb Hemost 2012;38:
10 New anticoagulant drugs and non-routine tests Prothrombin induced clotting time (PICT). Sensitive to both Dabigatran & Rivaroxaban. Reagents not widely available & standardisation unclear. Result depends on way test is performed. Test not widely available No therapeutic range for these anticoagulants with this test New anticoagulant drugs and non-routine tests Dilute Russell Viper Venon Time (drvvt). Sensitive to both Dabigatran & Rivaroxaban. Reagents widely available but test is not standardised for this application. Thrombin Generation (TG). Sensitive to both Dabigatran & Rivaroxaban. Reagents available but test is not standardised for this application. Research application but not routine testing. No therapeutic range for these anticoagulants with these tests or reagents 19 Harenberg J, et al. Semin Thromb Hemost 2012;38:16-22 Harenberg J, et al. Semin Thromb Hemost 2012;38:
11 New anticoagulant drugs - recommendations 1 New anticoagulant drugs - Westmead 21 Assess / consider need for testing in your lab or network. Discuss with clinicians. Are there any requests for testing. Should this testing be performed on site or sent away? Economics, staffing, instrumentation, availability after-hours and on weekends? Assess sensitivity of your current assays for both Dabigatran & Rivaroxaban. Standards easily available. Easy to assess sensitivity of current assays to these drugs. At least PT & APTT; if available, also TT & drvvt. Assess clotting times and normalised ratios (CT/CT of normal plasma) 22 Data not shown: Standard TT - Rivaroxaban insensitive; Dabigatran - oversensitive (even lowest drug dose = max TT). Standard anti-xa - Dabigatran insensitive; Rivaroxaban - oversensitive (even lowest drug dose = beyond assay detection range). Data Shown: PT, APTT & drvvt Clotting time data difficult to interpret in terms of effect given different baselines. Ratio data easier to interpret in terms of effect. Results not entirely within expectations. Apparent sensitivity Rivaroxaban drvvt > PT > APTT Apparent sensitivity Dabigatran drvvt ~ APTT > PT (but, possible dodgy point high drug level?) Presumably reagent dependent effects for PT & APTT. Data should be repeated for confirmation and drug evaluation range extended. (Key staff member on maternity leave; recent tender finalised & network will probably change routine PT & APTT reagents). 11
12 23 New anticoagulant drugs - recommendations 2 Follow the recommendations of experts. Australasian Society of Thrombsis and Haemostasis (ASTH) working group - recommendations for testing in progress. Others in progress/published Example: Consensus Document of FCSA, SIMeL, SIBioC and CISMEL (Italian Federation of Thrombosis Services; Italian Society of Laboratory Medicine; Italian Society of Clinical Biochemistry; Italian committee for standardization of laboratory tests): Dabigatran - recognises that this prolongs PT (but responsiveness poor) and prolongs APTT (better responsiveness, but non-linear); thus recommends modified TT or ECT. Rivaroxaban - recognises that this prolongs PT & APTT (linearly responsive), & drvvt (non-linearly responsive), or can be measured by anti-xa assay (but standard assay too sensitive); recommends PT (not INR) or modified anti-xa assay. Tripodi et al. Clin Chem Lab Med 2012, in press. 24 New anticoagulant drugs - Other considerations Interferences: Patients with certain haemostatic conditions (especially LA), may be difficult to assess (especially clot based tests) Beware usual pre-analytical issues (e.g., under-filled tubes, clotted samples, etc) & analytical interferences (e.g., lipaemia, icteria, haemolysis) Complications: Cannot properly measure many haemostasis analytes whilst patients are on anticoagulant drugs including Dabigatran & Rivaroxaban (e.g., antithrombin, fibrinogen, activated protein C resistance, protein C/S, LA). Drug levels / test results dependent on timing of dose (consider drug half-lives) Practicalities: Most routine labs only measure PT & APTT. ECT & (modified) TTs including HEMOCLOT (for Dabigatran) will not be difficult to set up on most coagulation analysers. (Modified) anti-xa (for Rivaroxaban) less easy to manage, but feasible if instrument includes a chromogenic detection system 12
13 New anticoagulant drugs - potential algorithm Basic coagulation assay panel PT APTT TT All normal Consider timing of tests in relation to last dose of OAC Consider specific individual test sensitivities to each OAC Significant OAC activity can be excluded Acknowledgments/Thanks: PT prolonged > APTT prolonged TT normal APTT prolonged > PT prolonged TT prolonged or non-clottable Suggestive of rivaroxaban effect (exclude warfarin effect, liver disease, etc) Confirmatory assay: anti-xa using specific rivaroxaban assay/standard (HEMOCLOT & ECT normal; drvvt prolonged) Suggestive of dabigatran effect (exclude heparin effect, low fibrinogen, etc) RCPA Haematology QAP staff, Westmead lab staff, Soma Mohammed, Roslyn Bonar, AIMS NSM 2012 organisers. Confirmatory assay: HEMOCLOT using specific dabigatran assay/standard (anti-xa normal; ECT prolonged; drvvt prolonged; fibrinogen normal unless dabigatran levels very high)
New Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
Anticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Committee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
Title of Guideline. Thrombosis Pharmacist)
Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Rivaroxaban (Xarelto ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
Comparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
The Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
indications November 2 nd, 2012 Dalhousie University
+ New oral anticoagulants: A review of current indications November 2 nd, 2012 Dr. Sudeep Shivakumar, Hematology Dalhousie University + Objectives es To review indications for anticoagulation To discuss
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
Guideline for patients receiving Dabigatran (Pradaxa ) requiring Emergency Surgery or treatment for Haemorrhage. Title of Guideline
Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Dabigatran (Pradaxa ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
Dr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
Dr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
Dabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
Cardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
New Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
Appendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
Introducing the Direct Oral Anticoagulants into Clinical Practice
Introducing the Direct Oral Anticoagulants into Clinical Practice Rory McSorley, Anticoagulant Pharmacist Anticoagulant Service Southern Health & Social Care Trust (SHSCT) 20 th May 2015 Content Discuss
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
Licence for use in the UK is expected before the end of 2011
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
Traditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
New anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
The management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Clinical Guideline N/A. November 2013
State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if
DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
Executive Summary. Motive for the request for advice
Executive Summary Motive for the request for advice Currently nearly 400,000 people in the Netherlands are being treated with anticoagulants of a type Vitamin K antagonists (VKAs). Although VKAs are very
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
DISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
Position Paper on Laboratory Testing for Patients Taking New Oral. Anticoagulants. Consensus Document of FCSA, SIMeL, SIBioC and
Position Paper on Laboratory Testing for Patients Taking New Oral Anticoagulants. Consensus Document of FCSA, SIMeL, SIBioC and CISMEL Armando Tripodi 1, Giancarlo Di Iorio 2, Giuseppe Lippi 3, Sophie
Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015
Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
Anticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
CLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10
Page 1 of 10 1.0 FOCUS: Mobilization with a Deep Vein Thrombosis (DVT). The purpose of this clinical practice guideline (CPG) is to ensure that new knowledge is integrated across Fraser Health and to standardize
Hot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5020
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5020 Dorothy M. (Adcock) Funk, M.D. Colorado Coagulation Karen A. Moser, M.D. Saint Louis University
Dabigatran revisited
Dabigatran revisited 22 Dabigatran has been available for general practitioners to prescribe since July, 2011. Twelve months later, over 14 000 patients were being dispensed this medicine. Dabigatran is
FDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
New Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
Time of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
East Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
New Oral Anticoagulants
Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15
The laboratory and new anticoagulant drugs
The laboratory and new anticoagulant drugs Andreas Hillarp Department of Clinical Chemistry and Transfusion Medicine Halland County Hospital, Sweden andreas.hillarp@regionhalland.se Disclosures for Andreas
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
NWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.
NWMIC Medicines FAQ New oral anticoagulants (NOACs) and management of dental patients - Date prepared: May 2013, updated November 2013 Summary In primary care; Consider liaising with the local hospital
Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )
Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-950:2014-2 Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) 1.
Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
Critical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Monitoring of new oral anticoagulants
Monitoring of new oral anticoagulants Jonathan Douxfils, Bernard Chatelain September 27th, 2012 1 Content Introduction Monitoring of NOACs Why? Dabigatran etexilate PD properties PK properties Rivaroxaban
Lupus anticoagulant Pocket card
Lupus anticoagulant Pocket card Issue number 5 2012 Antiphospholipid Syndrome 1 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and /or pregnancy loss
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
Disclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
Impact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
New Drugs for Blood Clots: Implications for Myeloprolierative Neoplasms (MPN)
New Drugs for Blood Clots: Implications for Myeloprolierative Neoplasms (MPN) Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia Center Division
LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban)
Sabiha Fatima Hussaini Sabiha.hussaini@salisbury.nhs.uk An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) April
4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN,
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention
Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment